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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
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Objective: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) in patients with 
infiltrative hepatocellular carcinoma (HCC) and to identify the prognostic factors associated with patient survival.
Materials and Methods: Fifty two patients who underwent TACE for infiltrative HCC were evaluated between 2007 and 
2010. The maximum diameter of the tumors ranged from 7 cm to 22 cm (median 15 cm). Of 46 infiltrative HCC patients 
with portal vein tumor thrombosis, 32 patients received adjuvant radiation therapy for portal vein tumor thrombosis after 
TACE.
Results: The tumor response by European Association for the Study of the Liver criteria was partial in 18%, stable in 47%, 
and progressive in 35% of the patients. The median survival time was 5.7 months (Kaplan-Meier analysis). The survival 
rates were 48% at six months, 25% at one year, and 12% at two years. In the multivariable Cox regression analysis, Child-
Pugh class (p = 0.02), adjuvant radiotherapy (p = 0.003) and tumor response after TACE (p = 0.004) were significant factors 
associated with patient survival. Major complications occurred in nine patients. The major complication rate was 
significantly higher in patients with Child-Pugh B than in patients with Child-Pugh A (p = 0.049, χ2 test).
Conclusion: Transcatheter arterial chemoembolization can be a safe treatment option in infiltrative HCC patients with Child 
Pugh class A. Child Pugh class A, radiotherapy for portal vein tumor thrombosis after TACE and tumor response are good 
prognostic factors for an increased survival after TACE in patients with infiltrative HCCs.
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common cancers worldwide with an increasing incidence in 
industrialized countries (1). Extensive ultrasound screening 
programs have helped to detect HCCs at an early stage 
during which they are amenable to various treatment 
options such as hepatic resection, percutaneous ethanol 
injection and thermoablation. Although these curative 
treatment options are known to improve survival, they can 
only be performed in 30% of patients with HCCs (2).
Treatment of infiltrative HCCs (i.e., with indistinct borders 
and a lack of typical enhancement pattern) is challenging 
for following reasons: 1) most infiltrative HCC patients 
present with advanced disease as infiltrative HCC may be 
difficult to diagnose given that it commonly lacks a well-
demarcated boundary on cross-sectional imaging and can 
http://dx.doi.org/10.3348/kjr.2014.15.4.464
pISSN 1229-6929 · eISSN 2005-8330
Korean J Radiol 15(4), Jul/Aug 2014kjronline.org 465
TACE for Infiltrative HCC
to the degree of liver function according to the Child-Pugh 
class.
The diameter of the tumors ranged from 7–22 cm (median 
15 cm [interquartile range 12–17 cm]) in maximum 
dimension before the initial treatment. Portal vein tumor 
thrombosis (main [n = 26], lobar or segmental [n = 20]) 
was observed in 46 patients (88%). According to the 
American Joint Committee on Cancer staging system (15), 
the number of patients in stages IIIA, IIIB, IIIC, IVA and 
IVB were three, 38, two, three, and six, respectively.
Transcatheter Arterial Chemoembolization
Superior mesenteric and common hepatic angiographies 
were performed to assess the vascular anatomy, tumor 
vascularity, tumor extent and portal vein patency. Following 
the selective cannulation of the right lobar, left lobar 
or proper hepatic artery using a microcatheter, 0.5 mg/
mL of cisplatin dissolved in distilled water, was infused 
into the hepatic artery for 15 minutes according to the 
tumor location. The infused dose of cisplatin was 2 mg/
kg (4 mL/kg) per patient’s weight. Before the 15-minute 
cisplatin infusion, some cisplatin was set aside to be 
mixed at a 1:1 ratio in an emulsion of iodized oil (Lipiodol, 
LaboratoireGuerbet, Cedex, France). It was infused into the 
segmental feeding artery after the cisplatin infusion (16). 
The embolization of the feeding arteries was performed by 
using 1-mm-diameter, absorbable gelfoam slurry (Gelfoam; 
Upjohn, Kalamazoo, MI, USA) until an arterial flow stasis 
was achieved. The 1 mm-diameter gelfoam slurry was 
manually made by cutting a 70 x 50 x 10 mm gelfoam 
sponge. The aforementioned TACE technique was applied to 
all patients included in this study. Less embolization with 
gelfoam slurry was performed in patients with extensive 
portal vein tumor thrombosis (i.e., main portal vein level) 
or poor hepatic reserve (Child-Pugh score B).
Adjuvant Radiation Therapy for Portal Vein Tumor 
Thrombosis
A radiotherapy focused on portal vein tumor thrombosis 
was planned after the identification of portal vein tumor 
thrombosis at the initial presentation or on follow-
up imaging after TACE and was started 0.5–4 months 
(mean 1.03 ± 0.64 months) after initial TACE for HCC with 
portal vein tumor thrombosis. Eligibility criteria for this 
radiotherapy were as follows: tumor thrombosis in the main, 
lobar or segmental portal vein, liver function of Child A or 
B, an Eastern Co-operative Oncology Group performance 
thus blend into the background of the cirrhotic liver (3, 
4), 2) it is difficult to evaluate the tumor extent within 
the liver due to the poorly delineated tumor boundary, 
and 3) because of its large, diffuse nature and propensity 
to involve the portal vein, diffuse infiltrative HCC may be 
difficult to treat and the treatment may increase the risk of 
serious complications (5). However, treatment options for 
patients with diffuse, infiltrative HCCs are limited and data 
are insufficient regarding the presentation, treatment and 
outcomes of patients with infiltrative HCCs (5).
In recent years, transcatheter arterial chemoembolization 
(TACE) has been considered for certain patients with 
unresectable HCC to be used for palliative purposes (6). 
Previous studies have clearly shown that TACE could safely 
prolong the survival in selected patients with unresectable 
HCC and with or without portal vein invasion (7-13). In 
this study, we evaluated the safety and efficacy of TACE in 
patients with infiltrative HCC and attempted to identify the 
prognostic factors associated with patient survival after 
TACE for infiltrative HCC.
MATERIALS AND METHODS
Patient Characteristics
This retrospective study was approved by our Institutional 
Review Board. The medical and imaging records of the 
enrolled patients were thoroughly reviewed. Indications of 
TACE for HCC at the authors’ institution are 1) unresectable 
HCC because of either advanced stage or insufficient hepatic 
reserve and 2) tumors that are unsuitable for other local 
treatments such as radiofrequency ablation or percutaneous 
ethanol injection because of tumor size, presence of 
multiple lesions (i.e., more than three), vascular invasion 
or subcapsular lesions. Exclusion criteria for TACE were 
any contraindication to the use of an arterial procedure, 
such as impaired clotting (platelet count < 50000/mm3 or 
prothrombin activity < 50%), bacterial infection or renal 
failure. Between January 2007 and January 2010, a total 
of 52 patients with infiltrative HCCs underwent TACE at our 
institution. There were 43 men and nine women ranging in 
age from 39–73 years (mean 56 ± 9 years). Most of these 
patients (82%) had underlying liver cirrhosis which had 
been diagnosed on imaging. The hepatitis B surface antigen 
was positive in 48 patients. The criteria for the diagnosis 
of HCC were based on the guidelines of the American 
Association for the Study of Liver Diseases (14). The number 
of patients in class A was 22 and in class B 30, referring 
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status of 0–2, no history of liver radiotherapy, tolerated 
initial TACE session and signed informed consent (11, 17). 
The presence of lymph nodes or distant metastases was not 
part of the exclusion criteria. An adjuvant radiation therapy 
was not performed in some patients who met those criteria, 
based on the attending physician’s preferences (11). A three-
dimensional conformal radiotherapy was used to determine 
target volumes, radiation ports and dose prescriptions 
by using a 3-dimensional radiotherapy planning system 
(Eclipse; Varian, Palo Alto, CA, USA). The gross tumor 
volume included the portal vein tumor thrombosis and a 
2- to 3-cm margin into the contiguous HCC. The dose per 
fraction to the planning target volume was 2 to 5 Gy at 
5 fractions per week. The total dose was determined by 
the volume of the normal liver and liver function and the 
maximum dose to the stomach or duodenum. A general 
guideline was that the fraction of the normal liver treated 
with more than 50% of the prescribed dose should be less 
than 50% of the normal liver volume (V50% < 50%) (17).
Follow-Up
A follow-up CT was performed one month after each 
TACE session in order to assess the tumor response to 
treatment and to allow a timely decision regarding 
subsequent treatment. The tumor extent was evaluated 
by measuring the diameter of the heterogeneous or 
homogeneous enhancing areas on arterial phase images, 
which corresponded to the washout on the portal or to a 
delayed phase on dynamic CT or MRI. The tumor response 
was as previously described, classified into four grades; 
complete response, partial response, stable disease and 
progressive disease, according to the European Association 
for the Study of the Liver criteria (5, 18, 19). A repeat TACE 
was indicated when there were new tumors, when there was 
tumor growth or when a residual tumor was detected. The 
treatment was terminated if the patient could not tolerate 
the procedure because of a decline in his/her clinical 
status.
Data Evaluation
The tumor response was evaluated 1 month after the 
initial TACE and was categorized as regression including 
complete response or partial response or non-regression 
including stable or progressive disease. Mortality 
resulting from TACE was defined as death within 30 days 
after TACE. According to the Society of Interventional 
Radiology reporting standards (20), major complications 
were defined as any event that resulted in the need for 
additional treatment, including an increased level of care, 
hospital stay beyond the observation status and including 
readmission after initial discharge, permanent adverse 
sequelae including substantial morbidity and disability, and 
death. All other complications were classified as minor. The 
overall patient survival was measured in months from the 
time of the first chemoembolization.
We evaluated the following prognostic factors for 
patient survival: age; sex; tumor size; Child-Pugh class; 
α-fetoprotein (AFP) level; portal vein tumor thrombosis; 
lymph node or distant metastasis; adjuvant radiotherapy 
for portal vein tumor thrombosis and tumor response. The 
tumor sizes and serum AFP levels were classified in two 
groups on basis of the median values.
Statistical Analysis
Statistical analysis was conducted using SPSS software 
(version 18.0; SPSS Inc., Chicago, IL, USA). We used χ2 test 
to determine whether there was any difference in the major 
complications rate according to the Child-Pugh classes. The 
cumulative survival curves were created using the Kaplan-
Meier method and were compared with the results of the 
log-rank test. Univariable and multivariable Cox regression 
analysis was performed to assess the factors associated with 
patient survival. We included significant factors or factors 
that showed a trend toward statistical significance in a 
multivariable model (p < 0.1) in the univariable analysis.
RESULTS
Complications and Tumor Response after TACE
The median number of treatment sessions was two per 
patient (range 1–17 sessions). A postembolization syndrome 
was developed in 19 of 52 study patients (37%), although 
it resolved within seven days without any treatment. 
Chemoembolization-related major complications occurred in 
nine (17%) study patients. The major complication rate was 
significantly higher in patients with Child-Pugh B (25.8%, 
8/31) than in patients with Child-Pugh A (4.7%, 1/21) (p 
= 0.049). An acute renal failure occurred in four patients, 
although these patients eventually recovered after medical 
treatment. A hepatic failure manifested by encephalopathy 
or ascites or both occurred in four patients. A hepatic 
abscess occurred in one patient and was successfully 
treated by percutaneous drainage and antibiotic therapy. 
One patient with Child-Pugh class B died within 30 days 
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after the time of chemoembolization because of a post-
chemoembolization-related hepatic failure. Therefore was 
the study patient mortality rate 2% (1 of 52).
A tumor response evaluation after TACE was possible in 
49 patients (94%, 49/52) because 1 month follow-up CT 
evaluation was not performed in three patients due to death 
within 1 month after TACE (n = 1) or an elevated creatinine 
level (> 2.0 mg/dL) (n = 2). After TACE, no patient showed 
complete response, nine patients (18%, 9/49) showed 
partial response (Fig. 1), 23 patients showed stable disease 
(47%, 23/49) and 17 (35%, 17/49) patients showed 
progressive disease despite the therapy. An objective 
tumor regression (≥ partial response) was achieved in nine 
patients (18%, 9/49) after TACE.
Follow-Up and Patient Survival
Thirty-two of the 52 study patients (62%) were treated 
with an adjuvant radiation therapy for portal vein tumor 
thrombosis after TACE. Fifty patients died and two remained 
alive during the follow-up period (mean 10.1 months) with 
a median survival period of 5.7 months. The patient survival 
rates were 48% at six months, 25% at one year and 12% at 
two years after chemoembolization (Fig. 2).
Factors Associated with Patient Survival
The following variables of p < 0.1, as seen in univariable 
analysis (Table 1), were entered into the multivariable 
Cox regression model: Child-Pugh class; tumor response 
and adjuvant radiation therapy after TACE. Multivariable 
A
C
B
D
Fig. 1. Images of 62-year-old patient with HCC.
A. Contrast-enhanced axial CT image in arterial phase showing diffuse infiltrative HCC (arrowheads) with right and main portal vein thrombosis 
(arrow). B. Hepatic angiographic image showing diffuse tumor staining in right lobe. C. Contrast-enhanced axial CT image in arterial phase 
obtained 1 month after initial chemoembolization shows lipiodol uptake in tumor and decreased extent of infiltrative HCC (arrowheads). D. 
Contrast-enhanced axial CT image in arterial phase after additional chemoembolizations (6 months after initial chemoembolization) shows further 
decreased extent of infiltrative HCC (arrowheads). HCC = hepatocellular carcinoma
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analysis also confirmed that the Child-Pugh class (p = 0.02), 
adjuvant radiation therapy after TACE (p = 0.003) and tumor 
response after TACE (p = 0.004) were significant factors 
associated with patient survival after TACE (Table 2). The 
Kaplan-Meier curves determined with these three factors are 
shown in Figure 3.
DISCUSSION
Infiltrative HCC is defined as a subtype of liver cancer 
that presents as an ill-defined, diffuse lesion. It accounts 
for 7 to 13% of HCCs (4, 21). As infiltrative HCC almost 
always manifests as an extensive, diffuse tumor and there 
are only few treatment options other than TACE. TACE is 
regarded as a strong relative contraindication for infiltrative 
HCC due to concerns regarding hepatic failure and the grave 
prognosis caused by a poor hepatic reserve (22). For this 
reason, although TACE is generally accepted as the only 
available treatment option, its efficacy for the treatment of 
infiltrative HCC has rarely been studied. However, Kneuertz 
et al. (5) and Jang et al. (23) have recently reported that 
TACE is both safe and feasible in selected patients with 
infiltrative HCC.
In our study, the median survival of the 52 study patients 
was 5.7 months. The one-year survival rate was 25% and 
the two-year survival rate was 12%. The results were quite 
comparable to those reported by Jang et al. (23), i.e., a 
median survival of 5.4 months, a survival rate of 29.4% 
at one year and a survival rate of 15.9% at two years. 
Approximately 60% of patients showed partial or stable 
disease after TACE. There was only one (2%) patient who 
Fig. 2. Kaplan-Meier curve shows overall cumulative survival 
rates in all 52 patients with infiltrative hepatocellular 
carcinomas.
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Table 1. Univariable Cox Regression Analysis of Prognostic Factors for Patient Survival Period
Hazard Ratio 95% CI P
Age 1.005 0.975–1.035 0.756
Male sex (n = 43) 1.212 0.585–2.511 0.606
Tumor size ≥ 15 cm (n = 26) 1.443 0.825–2.523 0.198
Child-Pugh class B (n = 30) 2.632 1.443–4.801 0.002
Serum AFP level ≥ 2530 ng/mL (n = 27) 1.088 0.623–1.902 0.766
Portal vein tumor thrombosis (n = 46) 1.799 0.712–4.547 0.215
Lymph node or distant metastasis (n = 10) 1.080 0.521–2.239 0.836
Adjuvant radiation therapy after TACE (n = 32) 3.372 1.817–6.257 < 0.001
Tumor response after TACE < 0.001
Partial response 1.000
Stable disease 1.779 0.816–3.880
Progressive disease 6.428 2.529–16.342
Note.— AFP = α-fetoprotein, CI = confidence interval, TACE = transcatheter arterial chemoembolization
Table 2. Multivariable Cox Regression Analysis of Prognostic Factors for Patient Survival Period
Hazard Ratio 95% CI P
Child-Pugh class B 2.138 1.128–4.062 0.02
Adjuvant radiation therapy after TACE 0.358 0.183–0.700 0.003
Tumor response after TACE 0.004
Partial response 1.000
Stable disease 1.869 0.825–4.229
Progressive disease 4.991 1.850–13.470
Note.— CI = confidence interval, TACE = transcatheter arterial chemoembolization
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died within 30 days of TACE and this was very similar to the 
peri-procedural mortality rate of 2.1% reported by Kneuertz 
et al. (5).
Our multivariable analysis showed that tumor response 
(partial response vs. stable disease, odds ratio [OR] 1.869, 
stable disease vs. progressive disease, OR 4.991, and p 
= 0.004), hepatic reserve (Child-Pugh class B, OR 2.138, 
p = 0.02), and adjuvant radiation therapy after TACE (OR 
0.358, p = 0.003) were significant independent prognostic 
factors for patient survival. We discovered that patients 
with either partial or stable disease had a better survival 
rate than those with progressive disease. As in some other 
recent reports (23), our study suggested that a poor hepatic 
reserve was associated with poor patient survival.
An adjuvant radiotherapy was considered once a portal 
vein tumor thrombosis was detected on initial or follow-up 
imaging. The rationale for the combined therapy was that a 
portal vein tumor thrombosis-focused adjuvant radiotherapy 
performed in patients with advanced HCC may decrease 
intravascular tumor growth and maintain portal flow, thus 
preserving liver function, inhibiting intrahepatic tumor 
spread and thus allowing additional TACE (24-26). Yoon et 
al. (17) found that adjuvant radiation therapy combined 
with TACE offers a safe and feasible treatment option for 
advanced HCC with portal vein tumor thrombosis. In their 
report (17), the median survival period after combining 
Fig. 3. Kaplan-Meier analysis for factors associated with patient survival.
A. Kaplan-Meier curves show patient survival rates according to Child-Pugh classiﬁcation. Median survival period was 10.0 months for patients 
with Child-Pugh class disease and 3.4 months for patients with Child-Pugh class B disease (p = 0.001). B. Kaplan-Meier curves show patient 
survival rates according to adjuvant radiation therapy performed after TACE. Median survival period was 8.0 months for patients who underwent 
adjuvant radiation therapy after TACE and 2.2 months for patients who did not undergo adjuvant radiation therapy after TACE (p < 0.001). C. 
Kaplan-Meier curves show patient survival rates according to tumor response. Median survival period was 9.7 months for patients with partial 
response, 7.3 months for patients with stable disease and 2.7 months for patients with progressive disease (p < 0.001). TACE = transcatheter 
arterial chemoembolization 
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TACE and radiotherapy for 412 HCC patients with portal 
vein tumor thrombosis was 10.6 months. In our series, a 
total of 32 patients (62%) underwent adjuvant radiotherapy 
and these patients showed a better survival rate (median 
survival period of eight months) than those who did not 
undergo an adjuvant radiotherapy (2.2 months). Therefore, 
we suggest that this combined approach provides an 
increased survival benefit for patients with infiltrative 
HCC, given that the majority of these patients may 
have combined portal vein tumor thrombosis for which 
radiotherapy may be an effective treatment (17).
When a physician treats patients with infiltrative HCCs, 
concerns regarding severe post-procedural complications 
arising from extensive tumor necrosis, may be an obstacle 
to perform an aggressive treatment (22). Indeed, TACE-
related major complications developed in nine patients 
(17%) in our study. This was more than the 3% seen in a 
previous study reporting the results of TACE in 362 patients 
with HCCs (6). The complication rate in our study was 
comparable to the 12.5% seen in a previous study (23) 
reporting the results of TACE in patients with infiltrative 
HCC. However, in our study occurred the majority of TACE-
related complications in patients with poor hepatic reserve 
and the major complications rate was significantly higher in 
patients with Child-Pugh B (25.8%) than in patients with 
Child-Pugh A (4.7%). Therefore, we believe that TACE can 
be safely performed as the initial treatment in patients with 
infiltrative HCC but with good hepatic reserve.
Previous studies (6, 27) found that the initial tumor size 
was a significant predictor of patient survival after TACE. 
However, the tumor size was not a significant factor for 
patient survival on multivariable analysis in our study. This 
might have resulted from differences in the demographics of 
patients (different composition of tumor types, tumor size). 
For instance, the majority of our study patients had a large 
tumor burden (range, 7–22 cm; median 15 cm [interquartile 
range 12–17 cm]). In addition, a previous study reporting 
the survival outcomes of TACE for infiltrative HCCs also 
found tumor size (tumor extent in their study) not as a 
significant factor on multivariable analysis (23).
The limitations of our study are the inclusion of patients 
treated at a single medical center only, the absence of a 
patient control group and the retrospective nature of the 
study. There are further prospective randomized studies 
required to evaluate the safety and efficacy of TACE for 
treating infiltrative HCC. In addition, a radiation therapy 
was started within one month after TACE in 15 patients 
among the 32 patients who underwent adjuvant radiation 
therapy for portal vein tumor thrombosis. Because tumor 
response was evaluated one month after TACE, this may 
have influenced the results of tumor response, although 
the radiation therapy focused on the portal vein tumor 
thrombosis, not on the primary HCCs.
In conclusion, TACE may be well-tolerated and can be a 
safe treatment option in patients with infiltrative HCC with 
Child Pugh class A. A disease of Child-Pugh class A, an 
adjuvant radiation therapy for portal vein tumor thrombosis 
after TACE and the tumor response are good prognostic 
factors for an increased patient survival after TACE in 
patients with infiltrative HCCs.
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